Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Werewolf Therapeutics Inc increased its cash reserves by 19.19%, or 25.05m. Cash Flow from Financing totalled 58.43m or 292.98% of revenues. In addition the company used 32.61m for operations while cash used for investing totalled 769.00k.
Cash flow per share | -1.32 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.38 |
---|---|
Tangible book value per share | 2.38 |
More ▼
Balance sheet in USDView more
Current ratio | 12.13 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.2419 |
---|---|
Total debt/total capital | 0.1948 |
More ▼